{"disease":{"id":"plasma-cell-neoplasm","name":"plasma cell neoplasm"},"drugs":{"marketed":[{"drug_id":"tagraxofusp","indication_name":"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Molecule 129","generic_name":"TAGRAXOFUSP","company_name":"Stemline Therapeeutics Inc","drug_phase":"marketed","molecular_target":"Elongation factor 2","drug_class":"CD123 Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Tagraxofusp works by binding to CD123 on cancer cells, causing them to die."},{"drug_id":"tagraxofusp","indication_name":"Blastic plasmacytoid dendritic cell neoplasm","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Molecule 129","generic_name":"TAGRAXOFUSP","company_name":"Stemline Therapeeutics Inc","drug_phase":"marketed","molecular_target":"Elongation factor 2","drug_class":"CD123 Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Tagraxofusp works by binding to CD123 on cancer cells, causing them to die."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06760052","title":"Longitudinal Data Registry of Plasma Cell Dyscrasia","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT00898040","title":"Study of DNA Samples From Patients With Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT00002678","title":"Combination Chemotherapy in Treating Patients With Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":595,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":false},{"nct_id":"NCT00303719","title":"Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":342,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT00049673","title":"Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":332,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":true},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07319897","title":"A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT00544115","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT03404193","title":"Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":235,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03386513","title":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":179,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04080531","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT03246906","title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT00005792","title":"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT04354246","title":"COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Compugen Ltd","has_results":false},{"nct_id":"NCT00474929","title":"Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT00003687","title":"Treatment for Chronic Pain in Patients With Advanced Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":false},{"nct_id":"NCT02220985","title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06271252","title":"A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"OriCell Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT00004088","title":"Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT03113643","title":"SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT00448201","title":"Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT00941720","title":"Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT03779854","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT00006890","title":"Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":false},{"nct_id":"NCT00790842","title":"Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":63,"lead_sponsor_name":"PrECOG, LLC.","has_results":true},{"nct_id":"NCT05805605","title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06013423","title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT00305812","title":"Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":false},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00792142","title":"Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT00053989","title":"NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT00602693","title":"T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT04216524","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00534118","title":"Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant","phase":"NA","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT00482378","title":"Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00772915","title":"Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT06006403","title":"Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT00281814","title":"Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant","phase":"","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT03974971","title":"Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population.","phase":"","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT00899080","title":"Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide","phase":"","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false},{"nct_id":"NCT07007052","title":"Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT02159495","title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT00477815","title":"Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06690827","title":"Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05336383","title":"Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00569309","title":"Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}